AbbVie

Open: 152.46 Close: 149.06 Change: -3.4

The top 13 things about AbbVie Company Inc found by an AI.

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, stock, …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. stock falls t Tuesday, still outperforms market - marketwatch.com. European Commission grants conditional marketing authorization for TEPKINLY.

Today's News

AbbVie Inc. stock falls t Tuesday, still outperforms market - marketwatch.com. Abbvie inc. stock fell t Tuesday. Allergan Aesthetics and Allergen, an AbbVie Company, to present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference. European Commission grants conditional marketing authorization for TEPKINLY as monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) European Commission approval of epcoritamab. AbbVie Inc. (ABBV) is a trending stock: facts to know before betting on it. The Zacks Large Cap Pharmaceuticals industry, to which Abbvie belongs, has lost 2.6% over this period. The Yes link below will take you out of the family of websites. AbbVies Venclyxto and a steroid dexamethasone failed to meaningfully increase the survival rate of patients without the disease worsening. The trial did not meet its primary endpoint, but the company is planning to discuss the data. AbbVie has opened a new €23m ($24.36m) European services hub in Dublin, Ireland. The site is now home to about 400 employees. The biopharmaceutical company is expanding its long-standing operations in Ireland. For AbbVie, its biggest risk is the competition about to hit its flagship drug Humira. Loss of patent exclusivity is a significant overhang–Abbvie expects its total sales will decline in 2023. European Commission approval of epcoritamab represents a significant milestone in our aspiration with Genmab to develop a potential core therapy for patients with B-cell malignancies, like DLBCL. TEPKINLY is now the second approved cancer treatment in the EU from our oncology portfolio. AbbVie has received approval in Japan for Epkinly for the treatment of large B-cell lymphoma, LBCL. The drug was launched in the US at the end of the second quarter and has also received a positive recommendation from regulatory authorities in Europe. AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma. Abbvie cautions that these forward-looking statements are subject. AbbVie Inc. (ABBV) stock price, quote & news - stock analysis. Abbvie Inc.s revenue was $58.05 billion, an increase of 3.30% compared to the previous years $56.20 billion. Analyst Consensus: Buy Stock Forecasts. Raymond James anticipates a resurgence of mid- to high-single-digit growth in both the top and bottom lines by 2025. Tepkinly has been approved for conditional marketing authorization by the European Commission.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, stock, European, Abbvie, Commission, Inc, treatment, and the most common words in the summary are: abbvie, job, news, get, company, best, stock, . One of the sentences in the summary was: stock falls t Tuesday, still outperforms market - marketwatch.com. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #job #news #get #company #best #stock.